RKO

RKO (Colorectal Cancer CDX Model) 

The RKO colorectal cancer line was derived from a colon carcinoma. It is microsatellite instability–high (MSI-H) due to mismatch repair deficiency. RKO provides a clinically relevant system for studying MSI-H colorectal cancers. Its reproducibility makes it a trusted colon cancer research tool. 

Key Features: 

• Derived from colorectal carcinoma. 

• MSI-high, mismatch repair–deficient. 

• Epithelial morphology. 

• Tumorigenic in xenografts. 

Applications: 
RKO is used to evaluate immunotherapy and targeted agents in MSI-H colorectal cancers. It supports biomarker discovery and drug resistance studies. Researchers use it in comparative studies against microsatellite-stable CRC lines. Its defined biology provides translational relevance.